Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NEK2 | P51955 | 2/20 | 0.51 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238160 | 0.92 | KDM4E (0.60) | ELANEKDM4ECYP2C19NEK2MALT1 | |
| SCHEMBL3436582 | 0.88 | POLB (0.52) | MALT1KMT2ATRPV1SMOTSHR | |
| SCHEMBL3436729 | 0.86 | CHRM4 (0.55) | ELANEKDM4ECYP2C19MALT1KMT2A | |
| SCHEMBL3436732 | 0.86 | HRH3 (0.48) | MALT1KMT2ATRPV1SMOTSHR | |
| SCHEMBL3436730 | 0.85 | TRPV1 (0.52) | MALT1KMT2ATRPV1SMOTSHR | |
| SCHEMBL3436721 | 0.85 | ALOX15 (0.58) | CYP2C19KMT2ATSHRALDH1A1MAPT | |
| SCHEMBL3436723 | 0.83 | HTT (0.52) | MALT1KMT2ATRPV1TSHRMAPT | |
| SCHEMBL3436727 | 0.82 | KMT2A (0.52) | KDM4EMALT1KMT2ATRPV1SMO | |
| SCHEMBL3436720 | 0.82 | MALT1 (0.45) | ELANEKDM4EMALT1KMT2ATRPV1 | |
| SCHEMBL3436393 | 0.80 | KDM4E (0.66) | ELANEKDM4ECYP2C19NEK2MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ELANE 2732/4885KDM4E 1834/4885CYP2C19 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.